Fulvestrant vs Vepdegestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Fulvestrant · Faslodex
Marketed by AstraZeneca
NCT00635713 · Phase 3 · completed
The trial randomized an estimated 588 participants and used double blinding to compare two active treatment groups: fulvestrant 125 mg plus anastrozole versus fulvestrant 250 mg plus anastrozole. Its primary endpoint was time to tumor progression, a clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
ClinicalTrials.gov records both arms as fulvestrant plus anastrozole. The published North American Trial 0021 (Osborne 2002) randomized fulvestrant 250 mg monthly against anastrozole 1 mg daily, double-blind and double-dummy.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Reported efficacy
Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59) (met)
Result source: NCT01602380
Vepdegestrant · Veppanu
Marketed by Rigel Pharmaceuticals and partners
NCT05654623 · Phase 3 · active, not recruiting
Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.
Next expected readout: December 2026 · NCT05909397 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)
Result source: NCT05654623
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fulvestrant | Vepdegestrant |
|---|---|---|
| PFS, median | 4.7 vs 3.8+0.9 vs placeboNCT0039045517 other results
| 3.7 vs 3.6vs FulvestrantNCT056546231 other result
|
| OS, median | 29.9 vs 26.4+3.5 vs placeboNCT0039045510 other results
| —Trial running · NCT05909397 |
| ORR | 20% vs 9%+11 vs placeboNCT003904559 other results
| 10.9% vs 3.6%vs FulvestrantNCT05654623 |
| Clinical benefit rate | 78.3% vs 74.1%vs AnastrozoleNCT016023809 other results
| 34.3% vs 28.7%vs FulvestrantNCT05654623 |
PFS, median
- Fulvestrant
- 4.7 vs 3.8+0.9 vs placeboNCT00390455
17 other results
- 16.6 vs 13.8 NCT01602380
- 4.8 vs 3.5 NCT00253422
- 4.1 vs 3.5 NCT00253422
- 7.5 vs 10 NCT02028507
- 8 NCT01300351
- 4.1 vs 3.8 NCT00390455
- 5.9 vs 3.3 NCT00390455
- 8 vs 10.6 NCT02028507
- 8.3 vs 5.7 NCT02675231
- 5.7 vs 5.7 NCT02675231
- 29.4 NCT03633331
- 5.4 NCT02860000
- 8 NCT03056755
- 5.6 NCT03056755
- 5.6 NCT03056755
- 4.6 NCT01670877
- 5.5 NCT01670877
- Vepdegestrant
- 3.7 vs 3.6vs FulvestrantNCT05654623
1 other result
- 5 vs 2.1 NCT05654623
OS, median
- Fulvestrant
- 29.9 vs 26.4+3.5 vs placeboNCT00390455
10 other results
- 20.1 vs 22.5 NCT00253422
- 20.2 vs 22.5 NCT00253422
- 33.7 vs 32 NCT02028507
- 37.8 vs 38.2 NCT00256698
- 41.3 NCT00075764
- 47.7 NCT00075764
- 35.6 NCT03633331
- 27.3 NCT03056755
- 29 NCT03056755
- 20.7 NCT03056755
- Vepdegestrant
- —Trial running · NCT05909397
ORR
- Fulvestrant
- 20% vs 9%+11 vs placeboNCT00390455
9 other results
- 13% vs 23% NCT00390455
- 38% vs 17% NCT00390455
- 46.1% vs 44.9% NCT01602380
- 29.9% NCT02860000
- 32.9% vs 13.9% NCT02675231
- 13.9% vs 13.9% NCT02675231
- 19.3% NCT03056755
- 17.5% NCT03056755
- 25.2% NCT03056755
- Vepdegestrant
- 10.9% vs 3.6%vs FulvestrantNCT05654623
Clinical benefit rate
- Fulvestrant
- 78.3% vs 74.1%vs AnastrozoleNCT01602380
9 other results
- 55% vs 55.1% NCT00256698
- 70% NCT00075764
- 73% NCT00075764
- 58.2% vs 38% NCT02675231
- 45.6% vs 38% NCT02675231
- 28.9% NCT02860000
- 46.2% NCT03056755
- 35.1% NCT03056755
- 38.3% NCT03056755
- Vepdegestrant
- 34.3% vs 28.7%vs FulvestrantNCT05654623
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Fulvestrant: 5 of 5 rows · Vepdegestrant: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fulvestrant | Vepdegestrant |
|---|---|---|
| Duration of Response time to event · months | 20 vs 13.2 Anastrozole months500 mga,b,c NCT01602380 · Phase 3 · combination 6 other source trials8.7 vs 12.8 Exemestane months NCT00253422 · Phase 3 · registry result, not featured evidence · combination 10.2 vs 12.8 Exemestane months NCT00253422 · Phase 3 · registry result, not featured evidence 9.7 vs 11.2 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 22.3 vs 18.2 Anastrozole months NCT00256698 · Phase 3 · registry result, not featured evidence · combination 9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination | NA vs 7.4 Fulvestrant monthsa,b,c NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Dropout rate | 89.1%500 mgd NCT01602380 · Phase 3 · combination show 40 more results47.5% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 31.7%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 21.2%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.2% NCT02447328 · Phase 4 · registry result, not featured evidence 0%Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination 0%Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneArm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence n/a: no completion milestoneArm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 21.6% NCT00390455 · Phase 3 · registry result, not featured evidence 32.4%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 64.7% NCT00256698 · Phase 3 · registry result, not featured evidence · combination 0% NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 1.1% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 87.5% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 8.2% NCT02860000 · Phase 2 · registry result, not featured evidence · combination 99.2%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 100%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 92.1%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 10.1%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 6.3%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 1.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02536742 · Phase 2 · registry result, not featured evidence —Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination 9.1%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 12.5%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 3.4%Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination —Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination 0% NCT02953860 · Phase 2 · registry result, not featured evidence · combination 0% NCT01441947 · Phase 2 · registry result, not featured evidence · combination 69.6%500 mg NCT00313170 · Phase 2 · registry result, not featured evidence 76.6%250 mg NCT00313170 · Phase 2 · registry result, not featured evidence 66.7%250 mg + loading dose NCT00313170 · Phase 2 · registry result, not featured evidence · combination | 7.8%d NCT05549505 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —500 mgd NCT01602380 · Phase 3 · combination show 40 more results10% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 3.2%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.5%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination — NCT02447328 · Phase 4 · registry result, not featured evidence —Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination —Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence 2% NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 1.4%Arm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence 3.4%Arm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 11.5% NCT00390455 · Phase 3 · registry result, not featured evidence 0%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 5% NCT00256698 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination — NCT03633331 · Phase 2 · registry result, not featured evidence · combination — NCT04224272 · Phase 2 · registry result, not featured evidence · combination — NCT02860000 · Phase 2 · registry result, not featured evidence · combination 15.7%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 11.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 10.3%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination — NCT03007979 · Phase 2 · registry result, not featured evidence · combination — NCT02536742 · Phase 2 · registry result, not featured evidence —Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination —Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination — NCT02953860 · Phase 2 · registry result, not featured evidence · combination — NCT01441947 · Phase 2 · registry result, not featured evidence · combination 0%500 mg NCT00313170 · Phase 2 · registry result, not featured evidence 2.1%250 mg NCT00313170 · Phase 2 · registry result, not featured evidence 3.9%250 mg + loading dose NCT00313170 · Phase 2 · registry result, not featured evidence · combination | —d NCT05549505 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 17.1%500 mgd NCT01602380 · Phase 3 · combination show 40 more results25% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 7.9%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 6.6%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 11.1% NCT02447328 · Phase 4 · registry result, not featured evidence 16.9%Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination 13.8%Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence 14.1% NCT02028507 · Phase 3 · registry result, not featured evidence · combination 6.2%Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence 13.8%Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination —Arm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Arm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 8.5% NCT00390455 · Phase 3 · registry result, not featured evidence 3.7%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 15.6% NCT00256698 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 38% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 15.7% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 25% NCT02860000 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 29.1%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 38.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30.2%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 19.5%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 30.8%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 73% NCT02536742 · Phase 2 · registry result, not featured evidence 0%Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination 18.2%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 37.5%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 10.5%Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination 18.5%Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination 6.3% NCT02953860 · Phase 2 · registry result, not featured evidence · combination 23.1% NCT01441947 · Phase 2 · registry result, not featured evidence · combination 8.7%500 mg NCT00313170 · Phase 2 · registry result, not featured evidence 8.5%250 mg NCT00313170 · Phase 2 · registry result, not featured evidence 18%250 mg + loading dose NCT00313170 · Phase 2 · registry result, not featured evidence · combination | 4%d NCT05549505 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 33 more resultshyperglycaemia 90% stomatitis 37.5% diarrhoea 35% NCT05631795 · Phase 4 · registry result, not featured evidence · combination diarrhoea 28.6% anaemia 22.2% fatigue 20.6% NCT04707196 · Phase 4 · registry result, not featured evidence · combination diarrhoea 29.9% neutropenia 24.8% anaemia 23.4% NCT04707196 · Phase 4 · registry result, not featured evidence · combination myalgia 12.3% nausea 12.3% back pain 11.1% NCT02447328 · Phase 4 · registry result, not featured evidence lethargy 64.5% arthralgia 42% hot flush 37.2% NCT00253422 · Phase 3 · registry result, not featured evidence · combination lethargy 64.4% vomiting 44.9% arthralgia 43.6% NCT00253422 · Phase 3 · registry result, not featured evidence neutrophil count decreased 63.1% fatigue 51% hypertension 36.9% NCT02028507 · Phase 3 · registry result, not featured evidence · combination fatigue (asthenia, lethargy, malaise) 60.2% hot flashes/flushes 45.7% pain - joint 45.1% NCT00075764 · Phase 3 · registry result, not featured evidence fatigue (asthenia, lethargy, malaise) 63.2% hot flashes/flushes 54.3% pain - joint 44% NCT00075764 · Phase 3 · registry result, not featured evidence · combination diarrhea 62.4% (placebo 21.9%) fatigue 55.3% (placebo 53.3%) rash acneiform 41.1% (placebo 4.4%) NCT00390455 · Phase 3 · registry result, not featured evidence 500 mg injection site reaction 11% pyrexia 10.1% fatigue 8.3% NCT01300351 · Phase 3 · registry result, not featured evidence arthralgia 11.7% fatigue 10.5% nausea 9% NCT00256698 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 92.4% white blood cell decreased 87% fatigue 84.8% NCT03633331 · Phase 2 · registry result, not featured evidence · combination diarrhoea 92.2% nausea 52.9% stomatitis 41.2% NCT04224272 · Phase 2 · registry result, not featured evidence · combination fatigue 83.3% anemia 62.5% neutrophil count decreased 60.4% NCT02860000 · Phase 2 · registry result, not featured evidence · combination diarrhoea 64.6% hyperglycaemia 59.8% nausea 46.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination asthenia 100% blood creatinine increased 100% diarrhoea 100% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 68.3% hyperglycaemia 64.3% nausea 54% NCT03056755 · Phase 2 · registry result, not featured evidence · combination hyperglycaemia 67.5% diarrhoea 54% nausea 40.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 70% hyperglycaemia 60% fatigue 50% NCT03056755 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg diarrhoea 77.9% fatigue 53.2% nausea 41.6% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg + 500 mg diarrhoea 79.5% fatigue 57.7% nausea 48.7% NCT02675231 · Phase 2 · registry result, not featured evidence · combination white blood cell count decreased 96.3% neutrophil count decreased 87% anemia 79.6% NCT03007979 · Phase 2 · registry result, not featured evidence · combination vomiting 60% anorexia 40% constipation 40% NCT01670877 · Phase 2 · registry result, not featured evidence · combination diarrhea 81.8% anorexia 63.6% aspartate aminotransferase increased 45.5% NCT01670877 · Phase 2 · registry result, not featured evidence · combination diarrhea 91.7% fatigue 50% nausea 50% NCT01670877 · Phase 2 · registry result, not featured evidence · combination hemoglobin - low 61.4% thrombocytopenia 61.4% nausea 59.6% NCT01142401 · Phase 2 · registry result, not featured evidence · combination hemoglobin - low 55.6% thrombocytopenia 55.6% diarrhea 51.9% NCT01142401 · Phase 2 · registry result, not featured evidence · combination fatigue 53.1% nausea 50% achiness 43.8% NCT02953860 · Phase 2 · registry result, not featured evidence · combination fatigue 76.9% anorexia 61.5% pain 53.8% NCT01441947 · Phase 2 · registry result, not featured evidence · combination 500 mg back pain 15.2% fatigue 15.2% nausea 15.2% NCT00313170 · Phase 2 · registry result, not featured evidence 250 mg nausea 25.5% hot flush 19.1% cough 12.8% NCT00313170 · Phase 2 · registry result, not featured evidence 250 mg + loading dose fatigue 22% nausea 18% back pain 16% NCT00313170 · Phase 2 · registry result, not featured evidence · combination | d hot flush 24.8% asthenia 20.8% constipation 15.8% NCT05549505 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation context differs: eligible sex differs (FEMALE versus ALL).
- bTreatment context differs: combination versus monotherapy.
- cThe assessment timepoint is not available for both results.
- dPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fulvestrant
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 4 more results
+ 65 further endpoints in the CSV export.
Vepdegestrant
Breast Cancer
Shared mechanism: Estrogen receptor · full Breast Cancer pipeline
Fulvestrant · Faslodex
Marketed by AstraZeneca
NCT00635713 · Phase 3 · completed
The trial randomized an estimated 588 participants and used double blinding to compare two active treatment groups: fulvestrant 125 mg plus anastrozole versus fulvestrant 250 mg plus anastrozole. Its primary endpoint was time to tumor progression, a clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
ClinicalTrials.gov records both arms as fulvestrant plus anastrozole. The published North American Trial 0021 (Osborne 2002) randomized fulvestrant 250 mg monthly against anastrozole 1 mg daily, double-blind and double-dummy.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Reported efficacy
Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59) (met)
Result source: NCT01602380
Vepdegestrant · Veppanu
Marketed by Rigel Pharmaceuticals and partners
NCT05654623 · Phase 3 · active, not recruiting
Randomized and controlled against fulvestrant, with progression read by blinded independent central review, but open-label. Of its two primary comparisons, progression-free survival was significantly longer in patients with ESR1 mutations (5.0 vs 2.1 months) but not in all randomized patients (3.8 vs 3.6 months, P=0.07), so the result is mixed.
Next expected readout: December 2026 · NCT05909397 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)); PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation (From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)): PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025). (mixed)
Result source: NCT05654623
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Fulvestrant: 8 of 8 rows · Vepdegestrant: 7 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fulvestrant | Vepdegestrant |
|---|---|---|
| Clinical Benefit responder rate · % of participants | 78.3% (n=230) vs 74.1% (n=232) Anastrozole500 mga,b,c NCT01602380 · Phase 3 · combination 3 other source trials55% (n=258) vs 55.1% (n=256) Anastrozole NCT00256698 · Phase 3 · registry result, not featured evidence · combination 45.6% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 58.2% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination | 34.3% (n=274) vs 28.7% (n=272) Fulvestranta,b,c NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Duration of Response time to event · months | 20 vs 13.2 Anastrozole months500 mga,b,c NCT01602380 · Phase 3 · combination 6 other source trials8.7 vs 12.8 Exemestane months NCT00253422 · Phase 3 · registry result, not featured evidence · combination 10.2 vs 12.8 Exemestane months NCT00253422 · Phase 3 · registry result, not featured evidence 9.7 vs 11.2 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 22.3 vs 18.2 Anastrozole months NCT00256698 · Phase 3 · registry result, not featured evidence · combination 9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination | NA vs 7.4 Fulvestrant monthsa,b,c NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| ORR responder rate · % of participants | 46.1% (n=193) vs 44.9% (n=196) Anastrozole500 mga,b,c NCT01602380 · Phase 3 · combination 5 other source trials20% (n=101) vs 9% (n=103) placebo NCT00390455 · Phase 3 · registry result, not featured evidence 13% (n=32) vs 23% (n=32) placebo NCT00390455 · Phase 3 · registry result, not featured evidence 38% (n=8) vs 17% (n=13) placebo NCT00390455 · Phase 3 · registry result, not featured evidence 13.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 32.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination | 10.9% (n=221) vs 3.6% (n=222) Fulvestranta,b,c NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| PFS time to event · months | 16.6 vs 13.8 Anastrozole months500 mga,b,c NCT01602380 · Phase 3 · combination 9 other source trials4.1 vs 3.5 Exemestane months NCT00253422 · Phase 3 · registry result, not featured evidence · combination 4.8 vs 3.5 Exemestane months NCT00253422 · Phase 3 · registry result, not featured evidence 7.5 vs 9.4 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 8 vs 10.6 Capecitabine months NCT02028507 · Phase 3 · registry result, not featured evidence · combination 4.7 vs 3.8 placebo months NCT00390455 · Phase 3 · registry result, not featured evidence 4.1 vs 3.8 placebo months NCT00390455 · Phase 3 · registry result, not featured evidence 5.9 vs 3.3 placebo months NCT00390455 · Phase 3 · registry result, not featured evidence 5.7 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 8.3 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination | 3.7 vs 3.6 Fulvestrant monthsd,a,b,c NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose5 vs 2.1 Fulvestrant months NCT05654623 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Dropout rate | 89.1%500 mge NCT01602380 · Phase 3 · combination show 39 more results47.5% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 31.7%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 21.2%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.2% NCT02447328 · Phase 4 · registry result, not featured evidence 0%Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination 0%Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneArm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence n/a: no completion milestoneArm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 21.6% NCT00390455 · Phase 3 · registry result, not featured evidence 32.4%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 64.7% NCT00256698 · Phase 3 · registry result, not featured evidence · combination 0% NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 1.1% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 87.5% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 8.2% NCT02860000 · Phase 2 · registry result, not featured evidence · combination 99.2%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 100%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 92.1%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy 0%Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · combination 10.1%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 6.3%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 1.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02536742 · Phase 2 · registry result, not featured evidence —Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination 9.1%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 12.5%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 3.4%Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination —Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination 0% NCT02953860 · Phase 2 · registry result, not featured evidence · combination 0% NCT01441947 · Phase 2 · registry result, not featured evidence · combination | 7.8%e NCT05549505 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —500 mge NCT01602380 · Phase 3 · combination show 39 more results10% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 3.2%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.5%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination — NCT02447328 · Phase 4 · registry result, not featured evidence —Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination —Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence 2% NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 1.4%Arm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence 3.4%Arm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 11.5% NCT00390455 · Phase 3 · registry result, not featured evidence 0%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 5% NCT00256698 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination — NCT03633331 · Phase 2 · registry result, not featured evidence · combination — NCT04224272 · Phase 2 · registry result, not featured evidence · combination — NCT02860000 · Phase 2 · registry result, not featured evidence · combination 15.7%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 11.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 10.3%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy —Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination — NCT03007979 · Phase 2 · registry result, not featured evidence · combination — NCT02536742 · Phase 2 · registry result, not featured evidence —Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination —Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination —Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination — NCT02953860 · Phase 2 · registry result, not featured evidence · combination — NCT01441947 · Phase 2 · registry result, not featured evidence · combination | —e NCT05549505 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 17.1%500 mge NCT01602380 · Phase 3 · combination show 39 more results25% NCT05631795 · Phase 4 · registry result, not featured evidence · combination 7.9%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 6.6%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 11.1% NCT02447328 · Phase 4 · registry result, not featured evidence 16.9%Faslodex + Arimidex NCT00253422 · Phase 3 · registry result, not featured evidence · combination 13.8%Faslodex + Placebo NCT00253422 · Phase 3 · registry result, not featured evidence 14.1% NCT02028507 · Phase 3 · registry result, not featured evidence · combination 6.2%Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence 13.8%Anastrozole & Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination —Arm I Anastrozole NCT00075764 · Phase 3 · registry result, not featured evidence —Arm II Anastrozole and Fulvestrant NCT00075764 · Phase 3 · registry result, not featured evidence · combination 8.5% NCT00390455 · Phase 3 · registry result, not featured evidence 3.7%500 mg NCT01300351 · Phase 3 · registry result, not featured evidence 15.6% NCT00256698 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 38% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 15.7% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 25% NCT02860000 · Phase 2 · registry result, not featured evidence · combination —Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 29.1%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 0%Cohort A: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination 38.1%Cohort B: Pre-treated With CDK 4/6 NCT03056755 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30.2%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 30%Cohort C: Pre-treated With Systemi NCT03056755 · Phase 2 · registry result, not featured evidence · combination 66.7%Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy 18.5%Crizotinib Oral Capsule [Xalkori] NCT03620643 · Phase 2 · registry result, not featured evidence · combination 19.5%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 30.8%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 73% NCT02536742 · Phase 2 · registry result, not featured evidence 0%Crossover: Neratinib + Fulvestrant NCT01670877 · Phase 2 · registry result, not featured evidence · combination 18.2%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 37.5%Part II: Neratinib + Fulvestrant ( NCT01670877 · Phase 2 · registry result, not featured evidence · combination 10.5%Arm B: Fulvestrant + Bortezomib NCT01142401 · Phase 2 · registry result, not featured evidence · combination 18.5%Arm C: Crossover From Arm A at Pro NCT01142401 · Phase 2 · registry result, not featured evidence · combination 6.3% NCT02953860 · Phase 2 · registry result, not featured evidence · combination 23.1% NCT01441947 · Phase 2 · registry result, not featured evidence · combination | 4%e NCT05549505 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 32 more resultshyperglycaemia 90% stomatitis 37.5% diarrhoea 35% NCT05631795 · Phase 4 · registry result, not featured evidence · combination diarrhoea 28.6% anaemia 22.2% fatigue 20.6% NCT04707196 · Phase 4 · registry result, not featured evidence · combination diarrhoea 29.9% neutropenia 24.8% anaemia 23.4% NCT04707196 · Phase 4 · registry result, not featured evidence · combination myalgia 12.3% nausea 12.3% back pain 11.1% NCT02447328 · Phase 4 · registry result, not featured evidence lethargy 64.5% arthralgia 42% hot flush 37.2% NCT00253422 · Phase 3 · registry result, not featured evidence · combination lethargy 64.4% vomiting 44.9% arthralgia 43.6% NCT00253422 · Phase 3 · registry result, not featured evidence neutrophil count decreased 63.1% fatigue 51% hypertension 36.9% NCT02028507 · Phase 3 · registry result, not featured evidence · combination fatigue (asthenia, lethargy, malaise) 60.2% hot flashes/flushes 45.7% pain - joint 45.1% NCT00075764 · Phase 3 · registry result, not featured evidence fatigue (asthenia, lethargy, malaise) 63.2% hot flashes/flushes 54.3% pain - joint 44% NCT00075764 · Phase 3 · registry result, not featured evidence · combination diarrhea 62.4% (placebo 21.9%) fatigue 55.3% (placebo 53.3%) rash acneiform 41.1% (placebo 4.4%) NCT00390455 · Phase 3 · registry result, not featured evidence 500 mg injection site reaction 11% pyrexia 10.1% fatigue 8.3% NCT01300351 · Phase 3 · registry result, not featured evidence arthralgia 11.7% fatigue 10.5% nausea 9% NCT00256698 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 92.4% white blood cell decreased 87% fatigue 84.8% NCT03633331 · Phase 2 · registry result, not featured evidence · combination diarrhoea 92.2% nausea 52.9% stomatitis 41.2% NCT04224272 · Phase 2 · registry result, not featured evidence · combination fatigue 83.3% anemia 62.5% neutrophil count decreased 60.4% NCT02860000 · Phase 2 · registry result, not featured evidence · combination diarrhoea 64.6% hyperglycaemia 59.8% nausea 46.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination asthenia 100% blood creatinine increased 100% diarrhoea 100% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 68.3% hyperglycaemia 64.3% nausea 54% NCT03056755 · Phase 2 · registry result, not featured evidence · combination hyperglycaemia 67.5% diarrhoea 54% nausea 40.5% NCT03056755 · Phase 2 · registry result, not featured evidence · combination diarrhoea 70% hyperglycaemia 60% fatigue 50% NCT03056755 · Phase 2 · registry result, not featured evidence · combination alanine aminotransferase increased 66.7% aspartate aminotransferase increased 66.7% dyspnea 50% NCT03620643 · Phase 2 · registry result, not featured evidence · monotherapy aspartate aminotransferase increased 74.1% nausea 74.1% alanine aminotransferase increased 63% NCT03620643 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg diarrhoea 77.9% fatigue 53.2% nausea 41.6% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg + 500 mg diarrhoea 79.5% fatigue 57.7% nausea 48.7% NCT02675231 · Phase 2 · registry result, not featured evidence · combination white blood cell count decreased 96.3% neutrophil count decreased 87% anemia 79.6% NCT03007979 · Phase 2 · registry result, not featured evidence · combination vomiting 60% anorexia 40% constipation 40% NCT01670877 · Phase 2 · registry result, not featured evidence · combination diarrhea 81.8% anorexia 63.6% aspartate aminotransferase increased 45.5% NCT01670877 · Phase 2 · registry result, not featured evidence · combination diarrhea 91.7% fatigue 50% nausea 50% NCT01670877 · Phase 2 · registry result, not featured evidence · combination hemoglobin - low 61.4% thrombocytopenia 61.4% nausea 59.6% NCT01142401 · Phase 2 · registry result, not featured evidence · combination hemoglobin - low 55.6% thrombocytopenia 55.6% diarrhea 51.9% NCT01142401 · Phase 2 · registry result, not featured evidence · combination fatigue 53.1% nausea 50% achiness 43.8% NCT02953860 · Phase 2 · registry result, not featured evidence · combination fatigue 76.9% anorexia 61.5% pain 53.8% NCT01441947 · Phase 2 · registry result, not featured evidence · combination | e hot flush 24.8% asthenia 20.8% constipation 15.8% NCT05549505 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation context differs: eligible sex differs (FEMALE versus ALL).
- bTreatment context differs: combination versus monotherapy.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fulvestrant
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 4 more results
+ 64 further endpoints in the CSV export.
Vepdegestrant
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fulvestrant's landscape · Vepdegestrant's landscape